Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib in Severe Fatigue From Post COVID Condition
NCT06597396Phase 2Active, not recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abrocitinib in post-COVID condition (PCC), sponsored by Beth Israel Deaconess Medical Center. Started Dec 2024; status: active, not recruiting.
02
Drugs
abrocitinib
03
Conditions
post-COVID condition (PCC)
Beyond the preview
Go deeper on NCT06597396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597396.